Skip to main content

Table 2 Clinicopathological and demographic characteristics of the study population classified by the participating center

From: Urine cell-based DNA methylation classifier for monitoring bladder cancer

   Hospital Clinic Barcelona Radboud University Medical Center, Nijmegen Saint John Emergency Clinical Hospital Bucharest MD Anderson Cancer Center Houston Total
Discovery phase Bladder cancer urine samples
 Stage
  Tis 5 1 1 7
  Ta 14 5 5 13 37
  T1 19 2 21 42
  > T2 9 16 25
 Grade
  LG 20 2 17 8 47
  HG 27 5 26 6 64
 Subtotal 47 7 43 14 111
Control urine samples
  BPH 8 3 11
  Urolithiasis 13 13
  Incontinence 1 1 2
  Benign bladder disease 4 5 1 10
  Urinary tract infection 1 8 4 13
  Non-urological diseases 6 2 8
 Subtotal 33 17 5 2 57
Validation phase R-PFBC URINE SAMPLES
 Stage
  Tis 2 1 8 2 13
  Ta 13 15 47 6 81
  T1 4 2 55 18 79
 Grade
  LG 14 8 74 96
  HG 5 10 36 26 77
 Subtotal 19 18 110 26 173
NR-PFBC urine samples
 Stage previous TURBT
  Tis 5 6 6 4 21
  Ta 32 56 36 26 150
  Ta + CIS 1 2 3
  T1 36 16 25 19 96
  T1 + CIS 5 3 8
  T2 3 3
  Tx 4 4
 Grade previous TURBT
  LG 34 35 38 19 126
  HG 52 43 29 35 159
 Subtotal 86 78 67 54 285
TOTAL 185 120 225 96 626
  1. LG low-grade, HG high-grade, TURBT transurethral resection bladder tumor, BPH benign prostate hyperplasia, CIS/Tis carcinoma in situ, BC bladder cancer, R-PFBC recurrent patients in follow-up for bladder cancer, NR-PFBC non-recurrent patients in follow-up for bladder cancer.